Linperlisib Combined With Chidamide in Patients With PTCL
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- Drug: cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone
- Registration Number
- NCT06421948
- Lead Sponsor
- Yanyan Liu
- Brief Summary
The goal of this clinical trial is to determine the maximum tolerated dose (MTD) of PI3Kδ inhibitor linperlisib when combined with fixed dose of HDAC inhibitor chidamide in participants with peripheral T-cell lymphoma (PTCL), and to compare the combination of linperlisib and chidamide to standard CHOP (cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone) regimen chemotherapy in the frontline treatment of PTCL to see which therapy is better.
- Detailed Description
In the phase Ib trial, participants with newly diagnosed or relapsed/refractory PTCL will receive fixed dose of chidamide (20 mg, twice a week) and escalating dose of linperlisib (40 mg, 60 mg, or 80 mg, once a day), to find out the optimal dose of linperlisib.
In the phase II trial, participants with newly diagnosed PTCL will be randomized into experimental arm (arm A) to receive linperlisib in combination with chidamide, or control arm (arm B) to receive standard CHOP regimen chemotherapy.
Interim efficacy assessment will be performed after three cycles of treatment. Responded participants will receive another three cycles of treatment. After a total of 6 cycles of treatment, participants can choose autologous hematopoietic stem cell transplantation, maintenance treatment with linperlisib and/or chidamide, or watch and wait.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 100
- Age 18-75 years at the time of inclusion (Age 18-80 years for phase Ib study)
- Patients with a newly diagnosed and histologically confirmed PTCL (phase Ib study includes both newly diagnosed and relapsed/refractory PTCL). Anaplastic large cell lymphoma and NK/T-cell lymphoma are not included.
- ECOG PS 0-2 at protocol entry
- Estimated life expectancy of 6 months or longer
- Measurable disease
- Hemoglobin ≥ 8 g/dL (≥5 mmol/l); Platelets ≥ 75 x 10E9/L; Absolute neutrophil count ≥ 1.0 x 10E9/L; Platelets ≥ 50 x 10E9/L permitted if documented bone marrow involvement; Serum bilirubin ≤ 1.5 x upper limit of normal (ULN); Serum glutamic-oxaloacetic transaminase (AST) and/or serum glutamic-pyruvic transaminase (ALT) ≤ 2.5 x ULN, or ≤ 5 x ULN if elevation is due to hepatic involvement by lymphoma; Serum creatinine ≤ 1.5 x ULNb; left ventricular ejection fraction (LVEF) ≥ 50%
- Women of childbearing potential must use safe anticonception (e.g. contraceptive pills, intrauterine devices etc.) during the study and 12 months after the last administration of study drugs; Male patients must use contraception for the duration of the study and 6 months after the last administration of study drugs if his partner is of childbearing potential
- Written informed consent
- Patients previously treated with PI3K inhibitor
- Patients previously treated with chidamide (phase Ib study is not limited by this item)
- Suspected or documented central nervous system involvement by lymphoma
- Patients with positive HIV and/or active hepatitis B and/or hepatitis C infection
- Patients with active, uncontrolled infections
- Unwillingness or inability to comply with the protocol
- Deemed 'unfit' by the treating physician
- Pregnant and/or breastfeeding women
- Concurrent severe and/or uncontrolled medical disease which is not lymphoma-related
- Patients with contraindications to chemotherapy
- Known hypersensitivity to one or more of the study drugs
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Orally administered, targeted therapy Linperlisib and chidamide Participants will receive a combination of linperlisib in combination with chidamide orally. Intravenously chemotherapy cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone Participants will receive standard CHOP regimen chemotherapy including cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone.
- Primary Outcome Measures
Name Time Method CRR Through study completion, an average of 3 years Complete response rate
- Secondary Outcome Measures
Name Time Method OS 12 months Overall survival
AE Through study completion, an average of 3 years Adverse event
PFS 12 months Progression-free survival
Trial Locations
- Locations (1)
Affiliated Cancer Hospital of Zhengzhou University
🇨🇳Zhengzhou, Henan, China